

## Dr Peter Noy PhD, MSci

Postdoctoral Research Fellow

**[School of Immunity and Infection \(/schools/immunity-infection/index.aspx\)](/schools/immunity-infection/index.aspx)**

### Contact details

Telephone **+44 (0)121 414 3733 (tel:+44 121 414 3733)**

Email **[p.j.noy@bham.ac.uk](mailto:p.j.noy@bham.ac.uk) (mailto:p.j.noy@bham.ac.uk)**

School of Immunity and Infection  
Medical and Dental Sciences  
Institute of Biomedical Research  
University of Birmingham  
Edgbaston  
Birmingham  
B15 2TT  
UK



### About

Dr Noy is a Cancer Research UK (CRUK) funded post-doctoral fellow. He is a member of the molecular angiogenesis laboratory run by **Professor Roy Bicknell** (</staff/profiles/iandi/bicknell-roy.aspx>), and works with a small team of students on characterising the novel tumour vasculature marker CLEC14A in tumour angiogenesis (blood vessel formation).

### Qualifications

- PhD Immunology
- MSci Biochemistry and Biological Chemistry

### Biography

Dr Noy studied his MSci in Biochemistry and Biological Chemistry at the University of Nottingham between 2003 and 2007. During this period he worked with Dr Eleni Stylianou on investigating the sub-nuclear localisation of the pleiotopic transcription factor NF- $\kappa$ B. This work inspired Dr Noy to continue academic research.

Following the completion of his undergraduate degree he moved to the University of Birmingham to do his PhD in 2007. Here he joined the laboratory of Dr Padma-Sheela Jayaraman. This was a productive period, working on the transcription factor PRH and the regulation of the VEGF receptor axis. Dr Noy published 7 papers from his PhD work including 3 first author publications.

After the award of his doctorate in 2011, Dr Noy joined the molecular angiogenesis laboratory to work on novel tumour endothelial markers. His role is to characterise CLEC14A in normal and pathological angiogenesis. He has also undertaken some teaching roles whilst in this position.

### Teaching

- **Medical Science BMedSc** (</undergraduate/courses/med/medical-sci.aspx>)
- **Medicine and Surgery MBChB** (</undergraduate/courses/med/medicine.aspx>)

### Publications

Noy,P., Sawasdichai,A., Jayaraman,P.-S. and Gaston,K. (2012) Protein kinase CK2 inactivates PRH/Hhex using multiple mechanisms to de-repress VEGF-signalling genes and promote cell survival. *Nucleic Acids Res*, 40: 9008–9020.

Noy,P., Gaston,K. and Jayaraman,P.-S. (2012) Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes. *Leuk Res*, 36: 1434–1437.

Noy,P., Williams,H., Sawasdichai,A., Gaston,K. and Jayaraman,P.-S. (2010) PRH/Hhex controls cell survival through coordinate transcriptional regulation of vascular endothelial growth factor signaling. *Mol Cell Biol*, 30: 2120–2134.

Soufi,A., Sawasdichai,A., Shukla,A., Noy,P., Dafforn,T., Smith,C., Jayaraman,P.-S. and Gaston,K. (2010) DNA compaction by the higher-order assembly of PRH/Hhex homeodomain protein oligomers. *Nucleic Acids Res*, 38: 7513–7525.

Soufi,A., Noy,P., Buckle,M., Sawasdichai,A., Gaston,K. and Jayaraman,P.-S. (2009) CK2 phosphorylation of the PRH/Hhex homeodomain functions as a reversible switch for DNA binding. *Nucleic Acids Res*, 37: 3288–3300.

Desjobert,C., Noy,P., Swingle,T.E., Williams,H., Gaston,K. and Jayaraman,P.-S. (2009) The PRH/Hhex repressor protein causes nuclear retention of Groucho/TLE co-repressors. *Biochem J*, 417: 121–132.

Yusuf,D., Butland,S.L., Swanson,M.I., Bolotin,E., Ticoll,A., Cheung,W.A., Zhang,X.Y., Dickman,C.T., Fulton,D.L., Lim,J.S., et al. (2012) The Transcription Factor Encyclopedia. *Genome Biol*, 13: R24

